A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
Tara Gurung,1 Deepson S Shyangdan,1 Joseph Paul O’Hare,2 Norman Waugh1 1Warwick Evidence, 2Division of Metabolic and Vascular Health, Warwick Medical School, University of Warwick, Coventry, UK Background: Dulaglutide is a new, long-acting glucagon-like peptide analogue in the treatment of...
Saved in:
Main Authors: | Gurung T, Shyangdan DS, O’Hare JP, Waugh N |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2015
|
Subjects: | |
Online Access: | https://doaj.org/article/bc350032f4514bc8a491ff16d157897f |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
by: Courtney H, et al.
Published: (2017) -
Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review
by: Berlie H, et al.
Published: (2012) -
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
by: Levin PA, et al.
Published: (2017) -
Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
by: Marina V. Shestakova, et al.
Published: (2017) -
Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020)